Microscale radiosynthesis, preclinical imaging and dosimetry study of [(18)F]AMBF(3)-TATE: A potential PET tracer for clinical imaging of somatostatin receptors.

BACKGROUND: Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging. Recent developments have greatly simplified such labeling: in particular, labeling of organotrifluoroborates via isotopic exchange can readily be performed in a single-step under aqueous conditions and without the need for HPLC purification. Though an automated synthesis has not yet been explored, microfluidic approaches have emerged for (18)F-labeling with high speed, minimal reagents, and high molar activity compared to conventional approaches. As a proof-of-concept, we performed microfluidic labeling of an octreotate analog ([(18)F]AMBF(3)-TATE), a promising (18)F-labeled analog that could compete with [(68)Ga]Ga-DOTATATE with the advantage of providing a greater number of patient doses per batch produced. METHODS: Both [(18)F]AMBF(3)-TATE and [(68)Ga]Ga-DOTATATE were labeled, the former by microscale methods adapted from manual labeling, and were imaged in mice bearing human SSTR2-overexpressing, rat SSTR2 wildtype, and SSTR2-negative xenografts. Furthermore, a dosimetry analysis was performed for [(18)F]AMBF(3)-TATE. RESULTS: The micro-synthesis exhibited highly-repeatable performance with radiochemical conversion of 50 ± 6% (n = 15), overall decay-corrected radiochemical yield of 16 ± 1% (n = 5) in ~40 min, radiochemical purity >99%, and high molar activity. Preclinical imaging with [(18)F]AMBF(3)-TATE in SSTR2 tumor models correlated well with [(68)Ga]Ga-DOTATATE. The favorable biodistribution, with the highest tracer accumulation in the bladder followed distantly by gastrointestinal tissues, resulted in 1.26 × 10(-2) mSv/MBq maximal estimated effective dose in human, a value lower than that reported for current clinical (18)F- and (68)Ga-labeled compounds. CONCLUSIONS: The combination of novel chemical approaches to (18)F-labeling and microdroplet radiochemistry have the potential to serve as a platform for greatly simplified development and production of (18)F-labeled peptide tracers. Favorable preclinical imaging and dosimetry of [(18)F]AMBF(3)-TATE, combined with a convenient synthesis, validate this assertion and suggest strong potential for clinical translation.